Bayer purchases heart drug for up to $310 mln

,

Bayer purchases heart drug for up to $310 mln

FRANKFURT, March 4 (Reuters) – Bayer (BAYGn.DE) said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfront.
 
The German drugmaker said it struck the deal with Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.
 
The drug acoramidis is under review to treat a progressive hear disease known as ATTR CM.

Reporting by Ludwig Burger, Editing by Rachel More

Source: Reuters

/by
You might also like
Novo NordiskNovo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
SPACES, James IanExploring Genentech’s SPACES
GavelSpanish competition watchdog fines drugmaker Leadiant 10.3 mln euros
FDAAlnylam wins adcomm’s support for heart disease drug despite FDA concerns
BayerBayer, Regeneron’s eye drug shown to work at higher dose, longer intervals
AstraZenecaRare disease drug development urgently needs more funding, experts say
Conditions suffered by diagnosed patientsThe digital secret to launch success in rare disease
AstraZenecaAstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio